Roche's hopes of Alecensa (alectinib) becoming the standard of care for advanced ALK-positive non-small cell lung cancer have been further boosted by fresh late-stage data confirming its superiority over Pfizer Inc.'s Xalkori (crizotinib) in terms of the drug's activity on brain metastases.
Data from two separate Phase III studies have been published ahead of presentations at the European Society for Medical Oncology...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?